Thank you for visiting FormulaScan . Please click on the Patent No to study the full patent document

US PATENTS IN PHARMACEUTICAL EXCIPIENTS AND FORMULATION GRANTED IN 2008



Patent No.: US7316819B2  Issued: 08/Jan/2008

Title: Oral peptide pharmaceutical dosage form and method of production

Applicant/Assignee: UNIGENE LABORATORIES, INC

Application No.: 10/094306   Filing Date: 07/Mar/2002

Abstract:

A pharmaceutical composition for oral delivery of a peptide is in the form of a lamination having at least two layers. The first layer of the lamination includes at least one pharmaceutically acceptable pH-lowering agent. The second layer includes a therapeutically effective amount of the peptide. The composition also includes at least one absorption enhancer effective to promote bioavailability of the peptide, which is preferably in the second layer, and an enteric coating surrounding the lamination. In a preferred dosage form of a tablet, a water-soluble coating is applied between the lamination and enteric coating which substantially prevents contact between the pH-lowering agent and the enteric coating. In a preferred embodiment, the peptide is salmon calcitonin, the pH-lowering agent is citric acid, and the absorption enhancer is lauroyl l-carnitine.

Priority: US20010274317P Applic. Date: 2001-03-08

Inventor: CROTTS GEORGE [US]; GHEBRE-SELLASSIE ISAAC [US]; SHETH ASHLESH [US]


Patent No.: US7318935B2  Issued: 15/Jan/2008

Title: PHARMACEUTICAL TABLETS WITH ACTIVE AND INACTIVE SEGMENTS

Applicant/Assignee: ACCU-BREAK TECHNOLOGIES, INC

Application No.: 11/693059   Filing Date: 29/Mar/2007

Abstract:

An immediate release compressed pharmaceutical tablet that has two or more segments and a top and a bottom and has a height that exceeds the width of the tablet. The height is measured vertically from the top to the bottom of the tablet while it is in the tablet die in which it is fully compressed, after compression has been completed. The width is measured as the greatest horizontal dimension of the tablet at a location halfway between the top and the bottom of the tablet, except that when the horizontal cross-section of the tablet is substantially rectangular, the width is defined by locating the two shorter sides of the perimeter of the horizontal cross-section, and measuring the length of a line that is at right angle to the shorter sides.

Priority: WO2005US18633 Applic. Date: 2005-05-23; WO2005US18638 Applic. Date: 2005-05-23; WO2005US18639 Applic. Date: 2005-05-23; WO2005US18631 Applic. Date: 2005-05-23; WO2005US18632 Applic. Date: 2005-05-23; US20040573134P Applic. Date: 2004-05-21; US20040573042P Applic. Date: 2004-05-21

Inventor: SOLOMON LAWRENCE [US]; KAPLAN ALLAN S [US]


Patent No.: US7318938B2  Issued: 15/Jan/2008

Title: Withania somnifera composition, method for obtaining same and pharmaceutical, nutritional and personal care formulations thereof

Applicant/Assignee: NATREON INC INDIAN HERBS RESEARCH & SUPPLY COMPANY LTD NATREON, INC INDIAN HERBS RESEARCH & SUPPLY CO., LTD

Application No.: 10/788130   Filing Date: 26/Feb/2004

Abstract:

This invention relates to a composition of the plant Withania Somnifera, and, more particularly to a high purity extract composition with advantageous levels of withanolide glycosides and oligosaccharides, a minimum of polysaccharides, and substantially low levels of free withaferin A and equivalents (withanolide aglycones), which composition provides enhanced cognition-enhancing effects for the user, and an extraction process for obtaining such composition, as well as pharmaceutical, nutritional and personal care use products thereof.

Priority: US2002-308714 Applic. Date: 2002-12-03

Inventor: GHOSAL SHIBNATH [IN]


Patent No.: US7320997B2  Issued: 22/Jan/2008

Title: Pharmaceutical compositions including carotenoid ester analogs or derivatives for the inhibition and amelioration of disease

Applicant/Assignee: CARDAX PHARMACEUTICALS, INC

Application No.: 10/793692   Filing Date: 04/Mar/2004

Abstract:

A method for inhibiting and/or ameliorating the occurrence of diseases associated with reactive oxygen species, reactive nitrogen species, radicals and/or non-radicals in a subject whereby a subject is administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative, or co-antioxidant formulation. The analog or derivative is administered such that the subject's risk of experiencing diseases associated with reactive oxygen species, reactive nitrogen species, radicals and/or non-radicals may be thereby reduced. In some embodiments, the invention may include a pharmaceutical composition including a carotenoid analog or derivative. The carotenoid analog may include a conjugated polyene with between 7 to 14 double bonds. The conjugated polyene may include a cyclic ring including at least one substituent.

The substituent may be coupled to the cyclic ring with an ester functionality. The pharmaceutical composition may be adapted to be administered to a human subject.

Priority: US2003-629538 Applic. Date: 2003-07-29; US20020399194P Applic. Date: 2002-07-29; US20030467973P Applic. Date: 2003-05-05; US20030472831P Applic. Date: 2003-05-22; US20030473741P Applic. Date: 2003-05-28; US20030485304P Applic. Date: 2003-07-03

Inventor: LOCKWOOD SAMUEL FOURNIER [US]; O'MALLEY SEAN [US]; WATUMULL DAVID G [US]; HIX LAURA M [US]; JACKSON HENRY [US]; NADOLSKI GEOFF [US]


Patent No.: US7320999B2  Issued: 22/Jan/2008

Title: Dimethyl fumarate for the treatment of multiple sclerosis

Applicant/Assignee: FUMAPHARM AG

Application No.: 10/197077   Filing Date: 17/Jul/2002

Abstract:

The present invention relates to the use of certain dialkyl fumarates for the preparation of pharmaceutical preparations for use in transplantation medicine or for the therapy of autoimmune diseases and said compositions in the form of micro-tablets or pellets. For this purpose, the dialkyl fumarates may also be used in combination with conventional preparations used in transplantation medicine and immunosuppressive agents, especially cyclosporines.

Priority: DE19981053487 Applic. Date: 1998-11-19; WO1999EP08215 Applic. Date: 1999-10-29; US2001-831620 Applic. Date: 2001-05-10

Inventor: JOSHI RAJENDRA KUMAR [CH]; STREBEL HANS-PETER [CH]


Patent No.: USRE40023E1  Issued: 22/Jan/2008

Title: Dietary and pharmaceutical compositions containing lyophilized lactic bacteria, their preparation and use

Applicant/Assignee:

Application No.: 11/375704   Filing Date: 15/Mar/2006

Abstract:

A pharmaceutical composition containing several different bacteria including Streptococcus thermophilus, Lactobacilli and Bifidobacteria is disclosed. The bacteria are present in the composition at a total concentration of 1x10<11 >to 1x10<13 >per gram. Further, methods of using the pharmaceutical are disclosed which include treatment of a gastrointestinal disorder and hypercholestermia. Also a method for modulating a host's immune response is disclosed.

Priority: IT1992MI00256 Applic. Date: 1992-02-10; US1995-448787 Applic. Date: 1995-05-24; US1993-117751 Applic. Date: 1993-09-08; US1992-983839 Applic. Date: 1992-12-01

Inventor: DESIMONE CLAUDIO [IT]


Patent No.: US7323172B2  Issued: 29/Jan/2008

Title: Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment

Applicant/Assignee: MEDIMMUNE, INC

Application No.: 10/962285   Filing Date: 08/Oct/2004

Abstract:

The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory syncytial virus (RSV) infection in a human, comprising administering to said human a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject.

The present invention also encompasses methods for treating or ameliorating symptoms associated with a RSV infection in a human, comprising administering to said human a therapeutically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention further encompasses compositions comprising antibodies or fragments thereof that immunospecifically bind to a RSV antigen, and methods using said compositions for detection or diagnosis a RSV infection.

Priority: US2001-996288 Applic. Date: 2001-11-28; US2000-724531 Applic. Date: 2000-11-28

Inventor: YOUNG JAMES F [US]; KOENIG SCOTT [US]; JOHNSON LESLIE S [US]; HUSE WILLIAM D [US]; WATKINS JEFFREY D [US]; WU HERREN [US]


Patent No.: US7323493B1  Issued: 29/Jan/2008

Title: Solid pharmaceutical composition containing benzofuran derivatives

Applicant/Assignee: SANOFI-AVENTIS

Application No.: 09/446601   Filing Date: 19/Jun/1998

Abstract:

The present invention relates to a solid pharmaceutical composition for oral administration characterized in that it comprises a benzofuran derivative with antiarrhythmic activity, or one of the pharmaceutically acceptable salts thereof, as an active principle, and a pharmaceutically acceptable nonionic hydrophilic surfactant optionally in combination with one or more pharmaceutical excipients.

Priority: FR19970007795 Applic. Date: 1997-06-23; WO1998FR01285 Applic. Date: 1998-06-19

Inventor: ABRAMOVICI BERNARD [FR]; GAUTIER JEAN-CLAUDE [FR]; GROMENIL JEAN-CLAUDE [FR]; MARRIER JEAN-MARIE [FR]


Patent No.: US7329418B2  Issued: 12/Feb/2008

Title: PHARMACEUTICAL TABLETS HAVING HEIGHT GREATER THAN WIDTH

Applicant/Assignee: ACCU BREAK TECHNOLOGIES, INC

Application No.: 11/678408   Filing Date: 23/Feb/2007

Abstract:

An immediate release compressed pharmaceutical tablet that has two or more segments and a top and a bottom and has a height that exceeds the width of the tablet. The height is measured vertically from the top to the bottom of the tablet while it is in the tablet die in which it is fully compressed, after compression has been completed. The width is measured as the greatest horizontal dimension of the tablet at a location halfway between the top and the bottom of the tablet, except that when the horizontal cross-section of the tablet is substantially rectangular, the width is defined by locating the two shorter sides of the perimeter of the horizontal cross-section, and measuring the length of a line that is at right angle to the shorter sides.

Priority: US20040573134P Applic. Date: 2004-05-21; WO2005US18639 Applic. Date: 2005-05-23; WO2005US18638 Applic. Date: 2005-05-23; WO2005US18633 Applic. Date: 2005-05-23; US2006-598306 Applic. Date: 2006-11-13; US2006-569343 Applic. Date: 2006-02-21; US20040573042P Applic. Date: 2004-05-21

Inventor: SOLOMON LAWRENCE [US]; KAPLAN ALLAN S [US]


Patent No.: US7329639B2  Issued: 12/Feb/2008

Title: Peptide useful in immunomodulation

Applicant/Assignee: MOR-RESEARCH APPLICATIONS LTD., CURETECH LTD MOR-RESEARCH APPLICATIONS LTD

Application No.: 11/411832   Filing Date: 27/Apr/2006

Abstract:

The present invention provides peptides and polynucleotides, and their use for immunomodulation, immunotherapy and vaccine particularly for anti-cancer therapy, and for diagnosis purposes. The immunomodulatory effect includes induction of proliferation and activation of peripheral blood lymphocytes and induction of an anti-tumor effect upon administration of peptides of the invention to subjects suffering from cancer.

Priority: IL20010145926 Applic. Date: 2001-10-15; US2004-821283 Applic. Date: 2004-04-09; WO2002IL00831 Applic. Date: 2002-10-15

Inventor: HARDY BRITTA [IL]; RAITER ANNAT [IL]; KLAPPER LEAH [IL]


Patent No.: US7332472B2  Issued: 19/Feb/2008

Title: Cyclosporine analogue mixtures and their use as immunomodulating agents

Applicant/Assignee: ISOTECHNIKA INC

Application No.: 11/118830   Filing Date: 28/Apr/2005

Abstract:

The invention is directed to isomeric mixtures of cyclosporine analogues that are structurally similar to cyclosporine A. The mixtures possess enhanced efficacy and reduced toxicity over the individual isomers and over naturally occurring and other presently known cyclosporines and cyclosporine derivatives. Embodiments of the present invention are directed toward cis and trans-isomers of cyclosporin A analogs referred to as ISATX247, and derivatives thereof. Mixtures of ISATX247 isomers exhibit a combination of enhanced potency and reduced toxicity over the naturally occurring and presently known cyclosporins. ISATX247 isomers and alkylated, arylated, and deuterated derivatives are synthesized by stereoselective pathways where the particular conditions of a reaction determine the degree of stereoselectivity.

The ratio of isomers in a mixture may range from about 10 to 90 percent by weight of the (E)-isomer to about 90 to 10 percent by weight of the (Z)-isomer, based on the total weight of the mixture.

Priority: US2002-274255 Applic. Date: 2002-10-17; US20010346201P Applic. Date: 2001-10-19; US20020370596P Applic. Date: 2002-04-05

Inventor: NAICKER SELVARAJ [CA]; YATSCOFF RANDALL W [CA]; FOSTER ROBERT T [CA]


Patent No.: US7335380B2  Issued: 26/Feb/2008

Title: Amlodipine free base

Applicant/Assignee: SYNTHON IP INC

Application No.: 10/024520   Filing Date: 21/Dec/2001

Abstract:

Amlodipine free base can be formulated into a convenient oral dosage form, especially a tablet, without excessive stickiness or tablet punch residue. The amlodipine free base can be crystalline Form I or a novel Form II. Methods of making and using the amlodipine free base are set forth.

Priority: US20000258613P Applic. Date: 2000-12-29

Inventor: LEMMENS JACOBUS M [NL]; PETERS THEODORUS H A [NL]; BENNEKER FRANCISCUS B G [NL]; KELTJENS ROLF [NL]


Patent No.: US7338668B2  Issued: 04/Mar/2008

Title: Drug carrier pellet production process

Applicant/Assignee:

Application No.: 10/182567   Filing Date: 16/Oct/2002

Abstract:

The invention provides a process for the production of drug carrier pellets comprising spray-drying a solution of a physiologically tolerable cellulosic binder containing a physiologically tolerable inert particulate carrier having a particle size D (v, 0.5) of less than 50 mum.

Priority: GB20000003782 Applic. Date: 2000-02-17; WO2001GB00704 Applic. Date: 2001-02-19

Inventor: LYNENSKHOLD EVA [DK]; JOERGENSEN LONE NOERGAARD [DK]


Patent No.: US7341720B2  Issued: 11/Mar/2008

Title: Targeting of glycoprotein therapeutics

Applicant/Assignee: GENZYME CORPORATION

Application No.: 11/398949   Filing Date: 05/Apr/2006

Abstract:

Methods of making ligand-decorated polymer conjugates of therapeutic glycoproteins are described. Improved targeting of glycoproteins to specific tissues is achieved by masking the natural carbohydrate and other surface determinants with high molecular weight polymers, such as, e.g., PEG, polysialic acid, etc., which in turn are decorated with target-specific ligands. In some embodiments, acid-labile linkages in such conjugates or rapidly degradable masking groups allow for the intracellular release of the polymer from the glycoprotein, for example, under conditions found in lysosomes.

Priority: US20050668920P Applic. Date: 2005-04-06

Inventor: STEFANO JAMES [US]


Patent No.: US7341742B2  Issued: 11/Mar/2008

Title: Simethicone containing tablet composition and method

Applicant/Assignee: L. PERRIGO COMPANY

Application No.: 10/260882   Filing Date: 30/Sep/2002

Abstract:

A process and pharmaceutical composition containing simethicone and magnesium carbonate allows a higher production rate of simethicone containing tablets and a more consistent end product tablet. The magnesium carbonate prevents sticking of simethicone to tablet compressing apparatuses, and may also prevent sticking of other excipients to tablet compressing apparatuses.

Priority:

Inventor: DANIELSON DOUGLAS W [US]; SCHUEHLE STEVEN S [US]; SHAH SHIRISH A [US]


Patent No.: US7348027B2  Issued: 25/Mar/2008

Title: Taste masked veterinary formulation

Applicant/Assignee: BAYER HEALTHCARE LLC

Application No.: 11/102426   Filing Date: 08/Apr/2005

Abstract:

A method of producing a self-take anthelmintic that includes active components that are undesirable to at least one sense of a target animal. The active ingredients including praziquantel are mixed with artificial beef and yeast components and subjected to a first compression. The resulting rough tablet is then ground to increase the density of the material by approximately 100% of the original density. Thereafter, the material is subjected to a second compression to form a final self-take tablet.

Priority:

Inventor: ROSE JOHN [US]; RUETER JOCHEM [US]


Patent No.: US7351429B1  Issued: 01/Apr/2008

Title: Oral solid preparation

Applicant/Assignee: KYORIN PHARMACEUTICAL CO., LTD

Application No.: 10/111422   Filing Date: 10/Nov/2000

Abstract:

The invention is to provide an oral solid pharmaceutical that is uniform in the content of KRP-197, having bladder-selective anticholinergic activity, being a therapeutic drug for pollakiuria and urinary incontinence, and being active with a very low dosage, that can be taken quantitatively, and that is easy in the handling. Since KRP-197 becomes unstable to light under the influence of additives, the invention is to select the additives to be used and to obtain a pharmaceutical with high stability. By formulating KRP-197 with drug-making carriers, a pharmaceutical that is uniform in the content, capable of taking quantitatively and easy in the handling has been provided. Furthermore, by using polyvinyl pyrrolidone for binder and by making into tablet coated with a coating base containing titanium dioxide and ferric oxide, a pharmaceutical capable of taking quantitatively and excellent in the light stability has been provided.

Priority: JP19990320585 Applic. Date: 1999-11-11; WO2000JP07904 Applic. Date: 2000-11-10

Inventor: OHYAMA TOSHINORI [JP]; OHISHI MASAHIKO [JP]; YAMAMOTO YASUHIRO [JP]


Patent No.: US7351710B2  Issued: 01/Apr/2008

Title: Preparation of amorphous form of indiplon

Applicant/Assignee: MAI DE LTD

Application No.: 11/347753   Filing Date: 06/Feb/2006

Abstract:

The present invention is directed to amorphous form of indiplon, to processes for preparing said amorphous form, to pharmaceutical compositions containing the same, and to method of treatment using the same. Additionally, the present invention also relates to the preparation of solid amorphous dispersion of indiplon and a carrier which includes PVP and solid PEG etc.

Priority: CN20051033218 Applic. Date: 2005-02-18

Inventor: HUANG LE [CN]; HUANG HUI MIN HE [US]


Patent No.: US7354584B2  Issued: 08/Apr/2008

Title: Recombinant IL-9 antibodies

Applicant/Assignee: MEDIMMUNE, INC

Application No.: 10/823253   Filing Date: 12/Apr/2004

Abstract:

The present invention provides novel antibodies that immunospecifically bind to an IL-9 polypeptide and compositions comprising said antibodies. The present invention also provides methods and compositions preventing, treating, managing, and/or ameliorating diseases and disorders associated with aberrant expression and/or activity of IL 9 or IL-9 receptor or subunits thereof, autoimmune diseases, inflammatory diseases, proliferative diseases, and infections comprising administration of one or more antibodies thereof that immunospecifically bind to an IL-9 polypeptide. The invention also encompasses methods and compositions for diagnosing, monitoring, and prognosing these disorders. The present invention further relates to articles of manufacture and kits comprising antibodies that immunospecifically bind to an IL-9 polypeptide.

Priority: US20030477797P Applic. Date: 2003-06-10; US20030462259P Applic. Date: 2003-04-11

Inventor: REED JENNIFER LYNNE [US]; WU HERREN [US]; TANG YING [US]; DAVIES JULIAN [US]; WATKINS JEFFRY D [US]


Patent No.: US7354597B2  Issued: 08/Apr/2008

Title: Microscale lyophilization and drying methods for the stabilization of molecules

Applicant/Assignee: MASSACHUSETTS INSTITUTE OF TECHNOLOGY

Application No.: 10/308579   Filing Date: 03/Dec/2002

Abstract:

Methods and systems are provided for microscale lyophilization or microscale drying of agents of interest, such as pharmaceutical agents or other molecules that are unstable or easily degraded in solution. The drying method includes (a) providing a liquid comprising an agent of interest dissolved or dispersed in a volatile liquid medium

(b) depositing a microquantity (between 1 nL and 10 muL) of the liquid onto a preselected site of a substrate

and then (c) drying the microquantity by volatilizing the volatile liquid medium to produce a dry, solid form of the agent of interest. The lyophilization method includes freezing the microquantity of liquid after step (b) and before step (c).

By processing the agent of interest in microquantities in controlled contact with a substrate surface, improved heat and mass transfer is provided, yielding better process control over drying of the agent of interest compared to conventional bulk drying or lyophilization.

Priority: US20010336793P Applic. Date: 2001-12-03

Inventor: JOHNSON AUDREY M [US]; CIMA MICHAEL J [US]; LANGER ROBERT S [US]


Patent No.: US7354601B2  Issued: 08/Apr/2008

Title: Particulate materials

Applicant/Assignee:

Application No.: 10/514895   Filing Date: 17/Nov/2004

Abstract:

A particulate coformulation, each particle comprising a core of an active substance surrounded by an excipient coating, the particles having a volume mean diameter of 10 mum or less, which on oral administration releases the active substance at a rate such that the time (Tmax) taken to attain the maximum active concentration in the bloodstream is one hour or less. The coformulation may be made using a Nektar(TM) SCF particle formation process.

Priority: GB20030010636 Applic. Date: 2003-05-08; GB20030029964 Applic. Date: 2003-12-24; WO2004GB01935 Applic. Date: 2004-05-05

Inventor: WALKER STEPHEN E [GB]; DAINTREE LINDA S [GB]; GERMAN CAROLINE S [GB]


Patent No.: US7358333B2  Issued: 15/Apr/2008

Title: Polypeptides of the IFNalpha-5 gene

Applicant/Assignee: GENODYSSE S.A

Application No.: 10/698402   Filing Date: 03/Nov/2003

Abstract:

The present invention relates to new polynucleotides derived from the nucleotide sequence of the IFNalpha-5 gene comprising new SNPs, and new polypeptides derived from the natural wild-type IFNalpha-5 protein comprising at least one mutation caused by at least one SNP of the invention as well as their therapeutic uses.

Priority: WO2002EP05458 Applic. Date: 2002-05-02; FR20010005919 Applic. Date: 2001-05-03

Inventor: ESCARY JEAN-LOUIS [FR]


Patent No.: US7361329B2  Issued: 22/Apr/2008

Title: Compositions for inducing an immune response

Applicant/Assignee: CHEMOCENTRYX, INC

Application No.: 10/001221   Filing Date: 30/Oct/2001

Abstract:

This application relates generally to enhancing immune responses. Such immune responses may be elicited by vaccine administration. Compositions and methods for inducing or enhancing an immune response to an antigen are provided. The compositions and methods are useful for, among other things, vaccine formulation for therapeutic and prophylactic vaccination (immunization) and for production of useful antibodies (e.g., monoclonal antibodies for therapeutic or diagnostic use).

Priority: US2001-834814 Applic. Date: 2001-04-12; WO2001US12162 Applic. Date: 2001-04-12; US20000198839P Applic. Date: 2000-04-21

Inventor: SCHALL THOMAS J [US]; HOWARD MAUREEN [US]; BERKOVITZ ROBERT [US]; PREMACK BRETT [US]; TALBOT DALE [US]


Patent No.: US7371369B2  Issued: 13/May/2008

Title: Polymeric interpenetrated network carrier and serial polymerization involving a crosslinked polymer network

Applicant/Assignee: ISP INVESTMENTS INC

Application No.: 10/705691   Filing Date: 10/Nov/2003

Abstract:

This invention relates to a highly stable, dense interpenetrated crosslinked polymer network (ICPN) containing (a) a crosslinked, network-forming primary polymer containing vinyl lactam and/or acrylic acid moieties, and (b) a secondary, optionally crosslinked, distinctly different polymer interpenetrated into the network of (a) and derived from a monomer selected from the group consisting of an acrylate and/or acrylamide monomer. The invention also relates to the oil-suspension, sequential polymerization of (a) and (b) for producing the above described interpenetrated polymeric network.

Priority:

Inventor: SHIH JENN S [US]


Patent No.: US7371819B2  Issued: 13/May/2008

Title: Polypeptides of the IFNalpha-17 gene

Applicant/Assignee: GENODYSSEE S.A

Application No.: 10/691653   Filing Date: 24/Oct/2003

Abstract:

The present invention relates to new polynucleotides derived from the nucleotide sequence of the IFNalpha-17 gene comprising new SNPs, and new polypeptides derived from the natural wild-type IFNalpha-17 protein comprising at least one mutation caused by at least one SNP of the invention, as well as their therapeutic uses.

Priority: WO2002EP05229 Applic. Date: 2002-04-23; FR20010005516 Applic. Date: 2001-04-24

Inventor: ESCARY JEAN-LOUIS [FR]


Patent No.: US7375111B2  Issued: 20/May/2008

Title: Compositions for affecting weight loss

Applicant/Assignee: OREXIGEN THERAPEUTICS, INC

Application No.: 10/828795   Filing Date: 21/Apr/2004

Abstract:

Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a melanocortin 4 receptor (MC4-R) compared to normal physiological conditions. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance alpha-MSH activity.

Priority: US20030466838P Applic. Date: 2003-04-29

Inventor: WEBER ECKARD [US]; COWLEY MICHAEL ALEXANDER [US]


Patent No.: US7384649B2  Issued: 10/Jun/2008

Title: Particulate compositions for pulmonary delivery

Applicant/Assignee: ADVANCED INHALATION RESEARCH, INC

Application No.: 11/633750   Filing Date: 05/Dec/2006

Abstract:

This invention concerns an improved particulate composition for delivering a drug to the pulmonary system. Applicants disclose a method of identifying an optimal form of aerodynamically light particles which are highly dispersible. The particles of the instant invention are made by creating hollow, spherical drug particles (i.e., progenitor particles) that collapse in the process of particle formation, leading to wrinkled, thin-walled drug particles of very low envelope density. Additionally, Applicants have found that such particles are especially optimal for inhaled aerosols when the surface area parameter (sigma) is greater than 2, optimally greater than 3.

Priority: US2002-300657 Applic. Date: 2002-11-20; US20010331708P Applic. Date: 2001-11-20

Inventor: BATYCKY RICHARD P [US]; EDWARDS DAVID A [US]; LIPP MICHAEL M [US]


Patent No.: US7390922B2  Issued: 24/Jun/2008

Title: Phenolic acid salts of gabapentin in liquid and/or semi-solid dosage forms and methods of use

Applicant/Assignee: KIEL LABORATORIES, INC

Application No.: 10/806260   Filing Date: 22/Mar/2004

Abstract:

The present invention relates to pharmaceutical compositions of gabapentin tannate, processes for production of those compositions and methods of use of those compositions. The present invention provides a novel process for preparation of the tannate salt of gabapentin in liquid or semi-solid dosage form for human and veterinary pharmaceutical use. Tannate salts of active pharmaceutical ingredients are used in sustained release applications and to improve certain organoleptic properties such as taste. The process may utilize either natural or synthetic tannic acid.

Priority: US20030457408P Applic. Date: 2003-03-25

Inventor: KIEL JEFFREY S [US]; THOMAS H GREG [US]; MANI NARASIMHAN [US]


Patent No.: US7393543B2  Issued: 01/Jul/2008

Title: Vaginally administratable progesterone-containing tablets and method for preparing same

Applicant/Assignee: BIOSOMA LTD FERRING B.V

Application No.: 10/832742   Filing Date: 26/Apr/2004

Abstract:

The present invention provides a method for preparing a tablet for the vaginal administration of progesterone for systemic use. The method comprises first mixing water with micronized progesterone, the total amount of water mixed with said micronized progesterone not exceeding the maximum wetting capacity of the micronized progesterone, drying the wetted, micronized progesterone

mixing the dry micronized progesterone with other pharmaceutically acceptable excipients or diluents

and

forming a tablet by direct compaction of the dry micronized progesterone. Tablets prepared by this method are also provided.

Priority: IL19980127129 Applic. Date: 1998-11-18; WO1999IL00619 Applic. Date: 1999-11-17; US2001-856417 Applic. Date: 2001-08-08

Inventor: JOSSIFOFF AZARIAH [IL]


Patent No.: US7399465B2  Issued: 15/Jul/2008

Title: Pharmaceutical compositions for treating arthritis and inflammatory disease

Applicant/Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Application No.: 10/967092   Filing Date: 15/Oct/2004

Abstract:

The biological effects of the cytokine TNF are mediated by binding to receptors on the surface of cells. This disclosure describes new proteins and polynucleotides that promote enzymatic cleavage and release of TNF receptors. Also provided are methods for identifying additional compounds that influence TNF receptor shedding. As the active ingredient in a pharmaceutical composition, the products of this invention increase or decrease TNF signal transduction, thereby alleviating the pathology of disease.

Priority: US2000-712813 Applic. Date: 2000-11-13; WO1999US10793 Applic. Date: 1999-05-14; US1998-081385 Applic. Date: 1998-05-14

Inventor: GATANAGA TETSUYA [US]; GRANGER GALE A [US]


Patent No.: US7399772B2  Issued: 15/Jul/2008

Title: Substituted benzimidazole dosage forms and method of using same

Applicant/Assignee: THE CURATORS OF THE UNIVERSITY OF MISSOURI CURATORS OF THE UNIVERSITY OF MISSOURI

Application No.: 10/641732   Filing Date: 15/Aug/2003

Abstract:

The present invention relates to pharmaceutical preparations comprising substituted benzimidazole proton pump inhibitors. There is provided a liquid or solid pharmaceutical composition consisting of a proton pump inhibitor and at least one buffering agent. Also provided is a pharmaceutical composition further comprising a parietal cell activator, an anti-foaming agent, a flavoring agent and combinations thereof

a method for treating acid-related gastrointestinal disorders by administering a solid pharmaceutical composition

and, a kit for the preparation of a liquid oral pharmaceutical composition. Dosage forms include: liquid, powder, tablet, capsule, effervescent powder, effervescent tablet, pellets, and granules.

Priority: US2002-068437 Applic. Date: 2002-02-05; US2000-481207 Applic. Date: 2000-01-11; US1998-183422 Applic. Date: 1998-10-30; US1996-680376 Applic. Date: 1996-07-15; US19960009608P Applic. Date: 1996-01-04

Inventor: PHILLIPS JEFFREY OWEN [US]


Patent No.: US7402593B2  Issued: 22/Jul/2008

Title: Monohydrated sodium salt of s-tenatoprazole and the use thereof in therapy

Applicant/Assignee: SIDEM PHARMA

Application No.: 10/561844   Filing Date: 17/Jun/2005

Abstract:

The present invention relates to S-tenatoprazole monohydrated sodium salt, represented by the following formula and the use thereof in therapy for the treatment of digestive diseases.

Priority: FR20040006617 Applic. Date: 2004-06-17; WO2005FR01528 Applic. Date: 2005-06-17

Inventor: COHEN AVRAHAM [IL]; SCHUTZE FRANCOIS [FR]; CHARBIT SUZY [FR]; MARTINET FREDERIC [FR]; FICHEUX HERVE [FR]; HOMERIN MICHEL [FR]


Patent No.: US7402663B2  Issued: 22/Jul/2008

Title: Modified peptide

Applicant/Assignee: UNIVERSITY OF ULSTER

Application No.: 10/469655   Filing Date: 05/Feb/2004

Abstract:

The invention provides a peptide based on biologically active CCK-8 having improved characteristics for the treatment of obesity and/or type 2 diabetes wherein the primary structure of CCK-8 is: Asp<1>Tyr<2>(SO3H)-Met<3>Gly<4>Trp<5>Met<6>Asp<7>Phe<8>amide (SEQ ID NO:1) and wherein the peptide has at least one amino add substitution and/or modification and is not Asp<1>-glucitol CCK-8. The invention also provides the use of the peptide in the preparation of a medicament to inhibit food intake, induce satiety, stimulate insulin secretion, moderate blood glucose excursions, enhance glucose disposal and/or exhibit enhanced stability in plasma compared to native CCK-8 and/or for treatment of obesity and/or type 2 diabetes.

Priority: GB20010005069 Applic. Date: 2001-03-01; WO2002GB00827 Applic. Date: 2002-02-28

Inventor: FLATT PETER RAYMOND [GB]; O'HARTE FINBARR PAUL MARY [GB]


Patent No.: US7404489B1  Issued: 29/Jul/2008

Title: Cyanocobalamin low viscosity aqueous formulations for intranasal delivery

Applicant/Assignee: QOL MEDICAL, LLC

Application No.: 10/814399   Filing Date: 31/Mar/2004

Abstract:

A stable pharmaceutical mercury-free aqueous solution of cyanocobalamin comprised of cyanocobalamin and water wherein said solution of cyanocobalamin is suitable for intranasal administration, has a viscosity less than about 1000 cPs, and wherein said solution of cyanocobalamin has a bioavailability of cyanocobalamin when administered intranasally of at least about 7% relative to an intramuscular injection of cyanocobalamin with the proviso that the solution is essentially free of mercury and mercury-containing compounds. The present invention is also directed towards a method for elevating the vitamin B12 levels in the cerebral spinal fluid (CSF) comprising administering intranasally a sufficient amount of a mercury-free cyanocobalamin solution so as to increase the average ratio of vitamin B12 in the CSF to that in the blood serum (B12 CSF/B12 Serumx100) to at least about 1.1 comprising intranasally administering an aqueous solution of a cyanocobalamin, wherein said solution of cyanocobalamin has a bioavailability of at least 7% relative to an intramuscular injection of a cyanocobalamin.

Priority: US2004-787385 Applic. Date: 2004-02-26; US20030451899P Applic. Date: 2003-03-04; US20030461583P Applic. Date: 2003-04-08; US20030474204P Applic. Date: 2003-05-29

Inventor: QUAY STEVEN C [US]; APRILE PETER C [US]; GO ZENAIDA O [US]; SILENO ANTHONY P [US]


Patent No.: US7405216B2  Issued: 29/Jul/2008

Title: Stable crystalline form of bifeprunox mesylate (7-[4-([1,1'-biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3H)-benzoxazolone monomethanesulfonate)

Applicant/Assignee: SOLVAY PHARMACEUTICALS, B.V

Application No.: 10/920361   Filing Date: 18/Aug/2004

Abstract:

The invention relates to a stable polymorphic form of the compound 7-[4-([1,1'-biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3H)-benzoxazolone monomethanesulfonate (INNM bifeprunox mesylate), a method for the preparation of said polymorphic form and its use in pharmaceutical products, especially in pharmaceutical products for the treatment of psychotic disorders and Parkinson's disease.

Priority:

Inventor: EIJGENDAAL IRENE [NL]; KLEIN GERRIT [NL]; TERHORST-VAN AMSTEL MARIA J L [NL]; ZWIER KLAAS [NL]; BRUINS NICO [NL]; RIGTER HENDRIKUS T [NL]; GOUT ERIK [NL]


Patent No.: US7413690B1  Issued: 19/Aug/2008

Title: Process and apparatus for producing spherical pellets using molten solid matrices

Applicant/Assignee: THE UNIVERSITY OF MISSISSIPPI

Application No.: 10/977163   Filing Date: 29/Oct/2004

Abstract:

A method and apparatus for forming pellets, the apparatus comprising a column for housing column liquid

column liquid

temperature controlling elements engaging the column and capable of maintaining a first and second temperature in the column liquid, and an injection orifice to introduce the liquid pellet composition to the column liquid.

Priority: US20030515361P Applic. Date: 2003-10-29

Inventor: CHEBOYINA SREEKHAR [US]; O'HAVER JOHN H [US]


Patent No.: US7413756B2  Issued: 19/Aug/2008

Title: Processes of making north american ginseng fractions, products containing them, and use as immunomodulators

Applicant/Assignee: C V TECHNOLOGIES INC FX LIFE SCIENCES INTERNATIONAL GMBH

Application No.: 11/114089   Filing Date: 26/Apr/2005

Abstract:

The invention is directed to chemical processes of preparing fractions form North American ginseng (Panax quinquefolium) and pharmaceutical compositions containing these fractions. The products of the present invention may be used to stimulate the production of cytokines and/or antibodies, or as therapeutics targeted at conditions characterized by low immunity, such as the common cold, influenza, chronic fatigue syndrome, AIDS and cancer.

Priority: US2002-187289 Applic. Date: 2002-07-02; US2000-581161 Applic. Date: 2000-07-27; WO1998US25724 Applic. Date: 1998-12-11; US19970069534P Applic. Date: 1997-12-12

Inventor: SHAN JACQUELINE J [CA]; PANG PETER K T [CA]; HUANG BUHAN [CA]; LING LEI [CA]


Patent No.: USRE40493E1  Issued: 09/Sep/2008

Title: Porous paclitaxel matrices and methods of manufacture thereof

Applicant/Assignee: ACUSPHERE, INC

Application No.: 11/213257   Filing Date: 26/Aug/2005

Abstract:

Paclitaxel is provided in a porous matrix form, which allows the drug to be formulated without Cremophor and administered as a bolus. The paclitaxel matrices preferably are made using a process that includes (i) dissolving paclitaxel in a volatile solvent to form a paclitaxel solution, (ii) combining at least one pore forming agent with the paclitaxel solution to form an emulsion, suspension, or second solution, and (iii) removing the volatile solvent and pore forming agent from the emulsion, suspension, or second solution to yield the porous matrix of paclitaxel. The pore forming agent can be either a volatile liquid that is immiscible with the paclitaxel solvent or a volatile solid compound, preferably a volatile salt. In a preferred embodiment, spray drying is used to remove the solvents and the pore forming agent. In a preferred embodiment, microparticles of the porous paclitaxel matrix are reconstituted with an aqueous medium and administered parenterally, or processed using standard techniques into tablets or capsules for oral administration.

Priority: US2001-798824 Applic. Date: 2001-03-02; WO2000US14578 Applic. Date: 2000-05-25; US20000186310P Applic. Date: 2000-03-02; US19990158659P Applic. Date: 1999-10-08; US19990136323P Applic. Date: 1999-05-27

Inventor: STRAUB JULIE A [US]; BERNSTEIN HOWARD [US]; CHICKERING III DONALD E [US]; KHATTAK SARWAT [US]; RANDALL GREG [US]


Patent No.: US7427414B2  Issued: 23/Sep/2008

Title: MODIFIED RELEASE ORAL DOSAGE FORM USING CO-POLYMER OF POLYVINYL ACETATE

Applicant/Assignee: ASTRON RESEARCH LIMITED

Application No.: 11/623560   Filing Date: 16/Jan/2007

Abstract:

Once a day modified release oral dosage form comprising of granules or pellets which are either compressed into tablet or filled inside the capsule, wherein the pellet has a core of active ingredient coated on non pareil seeds with a rate controlling functional coating of co-polymer of polyvinyl acetate optionally with an intermediate separating coating between the core and the functional coating layer.

Priority: IN2006MU00083 Applic. Date: 2006-01-18

Inventor: PATEL SHASHANK BABABHAI [IN]; YADAV KAMALA SULTANSINGH [IN]; MANDAL JAYANT KUMAR [IN]; MAHESHWARI KIRTI BANSIDHAR [IN]


Patent No.: US7427622B2  Issued: 23/Sep/2008

Title: Method of making and using theaflavin, theaflavin-3-gallate, theaflavin-3'-gallate and theaflavin 3,3'-digallate and mixtures thereof

Applicant/Assignee: NASHAI BIOTECH, LLC

Application No.: 11/640917   Filing Date: 19/Dec/2006

Abstract:

The present invention discloses methods of making a mixture of theaflavin, theaflavin-3-gallate, theaflavin-3'-gallate and theaflavin 3,3'-digallate, pharmaceutical compositions of the above mixture of theaflavins, diet supplement compositions of the above mixture of theaflavins and methods for using the above mixtures of theaflavin and pharmaceutical compositions thereof to treat or prevent various diseases. The present invention also discloses methods of making theaflavin, theaflavin-3-gallate, theaflavin-3'-gallate and theaflavin 3,3'-digallate, each as a separate compound, pharmaceutical compositions of the above compounds, diet supplement compositions of the above compounds and methods for using the above compounds to treat or prevent various diseases.

Priority: CN20021011512 Applic. Date: 2002-04-26; US2003-601314 Applic. Date: 2003-06-20; US2002-306204 Applic. Date: 2002-11-27; US20010333515P Applic. Date: 2001-11-28; US20020413576P Applic. Date: 2002-09-24

Inventor: ZHAO JIAN [US]; ZHOU RUI [CN]; CHEN HU [CN]


Patent No.: US7427638B2  Issued: 23/Sep/2008

Title: (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof

Applicant/Assignee: CELGENE CORPORATION

Application No.: 11/106142   Filing Date: 13/Apr/2005

Abstract:

Stereomerically pure (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, substantially free of its (-) isomer, and prodrugs, metabolites, polymorphs, salts, solvates, hydrates, and clathrates thereof are discussed. Also discussed are methods of using and pharmaceutical compositions comprising the (+) enantiomer of 2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione are disclosed. The methods include methods of treating and/or preventing disorders ameliorated by the reduction of levels of TNF-alpha or the inhibition of PDE4.

Priority: US2003-392195 Applic. Date: 2003-03-19; US20020366515P Applic. Date: 2002-03-20; US20030438450P Applic. Date: 2003-01-07

Inventor: MULLER GEORGE W [US]; SCHAFER PETER H [US]; MAN HON-WAH [US]; GE CHUANSHENG [US]


Patent No.: US7429394B2  Issued: 30/Sep/2008

Title: Ion binding compositions

Applicant/Assignee: RELYPSA, INC

Application No.: 11/095918   Filing Date: 30/Mar/2005

Abstract:

The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides core-shell compositions and pharmaceutical compositions thereof. Methods of use of the core-shell compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of phosphate imbalance disorders, hypertension, chronic heart failure, end stage renal disease, liver cirrhosis, chronic renal insufficiency, fluid overload, or sodium overload.

Priority: US2004-813872 Applic. Date: 2004-03-30; US2004-814749 Applic. Date: 2004-03-30; US2004-814527 Applic. Date: 2004-03-30; US2004-965274 Applic. Date: 2004-10-13

Inventor: CHARMOT DOMINIQUE [US]; FORDTRAN JOHN [US]; CHANG HAN TING [US]; CONNOR ERIC [US]; LIU MINGJUN [US]; KLAERNER GERRIT [US]


Patent No.: US7429562B2  Issued: 30/Sep/2008

Title: Cyclosporin analog formulations

Applicant/Assignee: ISOTECHNIKA INC., A CANADA CORPORATION ISOTECHNIKA INC

Application No.: 11/375532   Filing Date: 13/Mar/2006

Abstract:

The present invention relates to formulations containing cyclosporin analogs that are structurally similar to cyclosporin A, in particular isomeric mixtures of cyclosporin analogs that are structurally similar to cyclosporin A. The formulations form stable microemulsion preconcentrates and may provide superior drug bioavailability and/or may reduce one or more adverse effects associated with the administration of cyclosporin. Also disclosed are methods for using and preparing the formulations.

Priority: US2002-274419 Applic. Date: 2002-10-17; US20020370597P Applic. Date: 2002-04-05; US20010346201P Applic. Date: 2001-10-19

Inventor: NAICKER SELVARAJ A [CA]; YATSCOFF RANDALL W [CA]; FOSTER ROBERT T [CA]


Patent No.: US7432097B2  Issued: 07/Oct/2008

Title: Phytases, nucleic acids encoding them and methods of making and using them

Applicant/Assignee: VERENIUM CORPORATION

Application No.: 10/933115   Filing Date: 01/Sep/2004

Abstract:

In one aspect, the invention provides a purified and modified phytase enzyme from Escherichia coli K12 appA phytase. The enzyme has phytase activity and improved thermal tolerance as compared with the wild-type enzyme. In addition, the enzyme has improved protease stability at low pH. Glycosylation of the modified phytase provided a further improved enzyme having improved thermal tolerance and protease stability. The enzyme can be produced from native or recombinant host cells and can be used to aid in the digestion of phytate where desired. In one aspect, the phytase of the present invention can be used in foodstuffs to improve the feeding value of phytate rich ingredients.

Priority: US2001-866379 Applic. Date: 2001-05-24; US2000-580515 Applic. Date: 2000-05-25; US1999-318528 Applic. Date: 1999-05-25; US1999-291931 Applic. Date: 1999-04-13; US1999-259214 Applic. Date: 1999-03-01; US1997-910798 Applic. Date: 1997-08-13

Inventor: SHORT JAY M [US]; KRETZ KEITH A [US]; GRAY KEVIN A [US]; BARTON NELSON ROBERT [US]; GARRETT JAMES B [US]; O'DONOGHUE EILEEN [US]; BAUM WILLIAM [US]; ROBERTSON DAN E [US]; ZORNER PAUL [US]


Patent No.: US7432240B2  Issued: 07/Oct/2008

Title: Fumaric Acid Amides

Applicant/Assignee: FUMAPHARM AG BIOGEN IDEC INTERNATIONAL GMBH

Application No.: 11/421083   Filing Date: 31/May/2006

Abstract:

Fumaric acid amides of the general formula (I) wherein R<1 >represents OR<3 >or a D- or L-amino acid radical -NH-CHR<4>-COOH bonded via an amide bond, wherein R<3 >is hydrogen, a straight-chained or branched, optionally substituted C1-24 alkyl radical, a phenyl radical or C6-10 aralkyl radical and R<4 >is a side chain of a natural or synthetic amino acid and R<2 >represents a D- or L-amino acid radical -NH-CHR<5>-COOH bonded via an amide bond or a peptide radical comprising 2 to 100 amino acids bonded via an amide bond, wherein R<5 >is a side chain of a natural or synthetic amino acid, are used for preparing a drug (1) for the therapy of an autoimmune disease

(2) for use in transplantation medicine

(3) for the therapy of mitochondrial diseases

or (4) for the therapy of NF-kappaB mediated diseases.

Priority: DE20011001307 Applic. Date: 2001-01-12; DE20011033004 Applic. Date: 2001-07-06; US2003-433295 Applic. Date: 2003-06-02; WO2002EP00107 Applic. Date: 2002-01-08

Inventor: JOSHI RAJENDRA KUMAR [CH]; STREBEL HANS-PETER [CH]


Patent No.: US7435427B2  Issued: 14/Oct/2008

Title: Pharmaceutical semi-solid composition of isotretinoin

Applicant/Assignee: GALEPHAR M/F

Application No.: 10/380619   Filing Date: 30/Jul/2003

Abstract:

An oral pharmaceutical composition of isotretinoin containing at least two lipidic excipients, one of them being hydrophilic (i.e. having an HLB value superior or equal to 10), the other being an oily vehicle.

Priority: WO2001BE00163 Applic. Date: 2001-09-21; WO2000BE00111 Applic. Date: 2000-09-22

Inventor: VANDERBIST FRANCIS [BE]; SERVAIS CECILE [BE]; BAUDIER PHILIPPE [BE]


Patent No.: US7435427B2  Issued: 14/Oct/2008

Title: Pharmaceutical semi-solid composition of isotretinoin

Applicant/Assignee: GALEPHAR M/F

Application No.: 10/380619   Filing Date: 30/Jul/2003

Abstract:

An oral pharmaceutical composition of isotretinoin containing at least two lipidic excipients, one of them being hydrophilic (i.e. having an HLB value superior or equal to 10), the other being an oily vehicle.

Priority: WO2001BE00163 Applic. Date: 2001-09-21; WO2000BE00111 Applic. Date: 2000-09-22

Inventor: VANDERBIST FRANCIS [BE]; SERVAIS CECILE [BE]; BAUDIER PHILIPPE [BE]


Patent No.: US7438924B2  Issued: 21/Oct/2008

Title: Dry granulated formulations of azithromycin

Applicant/Assignee: PFIZER INC

Application No.: 10/355575   Filing Date: 31/Jan/2003

Abstract:

This invention relates to a pharmaceutical formulation, in the form of a tablet, sachet or powder for suspension dosage form, which comprises dry granulated particles of a non-dihydrate form of azithromycin and, optionally, one or more pharmaceutically acceptable excipients. Preferably, the pharmaceutical formulation is a tablet containing between about 40%, by weight, to about 90%, by weight, non-dihydrate azithromycin. More preferably, the pharmaceutical formulation contains non-dihydrate azithromycin selected from the forms B, D, E, F, G, H, J, M, N, O, P, Q, R, or mixtures thereof. Even more preferably, the invention relates to a pharmaceutical formulation wherein the dosage of azithromycin is 250 mgA, 500 mgA, 600 mgA or 1000 mgA.

The present invention further relates to a dry granulated azithromycin particle, comprising a form of azithromycin, selected from forms D, E, F, G, H, J, M, N, O, P, Q, R and mixtures of non-dihydrate forms, and at least one pharmaceutically acceptable excipient.

Priority: US20020354041P Applic. Date: 2002-02-01

Inventor: JOHNSON BARBARA A [US]; QUAN ERNEST S [US]


Patent No.: US7438929B2  Issued: 21/Oct/2008

Title: Multi-particulate form of medicament, comprising at least two differently coated forms of pellet

Applicant/Assignee: ROEHM GMBH & CO. KG

Application No.: 10/949323   Filing Date: 27/Sep/2004

Abstract:

The invention relates to a multiparticulate drug form suitable for uniform release of an active pharmaceutical ingredient in the small intestine and in the large intestine, comprising at least two forms of pellets A and B which comprise an active pharmaceutical ingredient in the core and have different polymer coatings which determine the release of the active ingredient at different pH values, characterized in that pellet form A is provided with an inner polymer coating which enables continuous release of active ingredient, and has an outer enteric coating which rapidly dissolves above about pH 5.5, and pellet form B is provided with a polymer coating which, in the USP release test, releases less than 20% of the active ingredient at pH 6.8 in 6 hours and releases more than 50% of the active ingredient at pH 7.2 in 6 hours.

The invention additionally relates to a process for producing the multiparticulate drug form and to the use of pellet forms A and B for producing the drug form.

Priority: DE20011004504 Applic. Date: 2001-01-31; DE20011004880 Applic. Date: 2001-02-01; US2003-239209 Applic. Date: 2003-02-12; WO2001EP02679 Applic. Date: 2001-03-09

Inventor: BECKERT THOMAS [DE]; PETEREIT HANS-ULRICH [DE]; DRESSMAN JENNIFER [DE]; RUDOLPH MARKUS [DE]


Patent No.: US7439251B2  Issued: 21/Oct/2008

Title: Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor

Applicant/Assignee: ISREAL INSTITUTE FOR BIOLOGICAL RESEARCH ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH

Application No.: 10/512673   Filing Date: 08/Jul/2005

Abstract:

There are provided methods for the treatment of diseases involving dysfunction of the peripheral and central nervous system comprising administering one or more spiro compounds. Also provided are pharmaceutical compositions useful in such methods, compounds for use in the preparation of such pharmaceutical compositions, processes for preparing compounds useful in the practice of such methods, and some novel such compounds per se.

Priority: US20020377433P Applic. Date: 2002-05-03; WO2003IL00357 Applic. Date: 2003-05-01

Inventor: FISHER ABRAHAM [IL]; BAR-NER NIRA [IL]; KARTON YISHAI [IL]


Patent No.: US7456312B2  Issued: 25/Nov/2008

Title: Phenolic acid salts of gabapentin in solid dosage forms and methods of use

Applicant/Assignee: KIEL LABORITIES, INC

Application No.: 10/805806   Filing Date: 22/Mar/2004

Abstract:

The present invention relates to pharmaceutical compositions of gabapentin tannate in solid dosage form, processes for production of those compositions and methods of use of those compositions. Tannate salts of active pharmaceutical ingredients are used in sustained release applications and to improve certain organoleptic properties such as taste. The process may utilize either natural or synthetic tannic acid.

Priority: US20030457399P Applic. Date: 2003-03-25

Inventor: KIEL JEFFREY S [US]; THOMAS H GREG [US]; MANI NARASIMHAN [US]


Patent No.: US7459173B2  Issued: 02/Dec/2008

Title: Medicament for prevention and treatment of bone fracture and osteoporosis

Applicant/Assignee: SAGITTARIUS LIFE SCIENCE CORP

Application No.: 10/976599   Filing Date: 28/Oct/2004

Abstract:

A pharmaceutical composition which can be used to prevent and treat bone fracture and osteoporosis. The composition is composed of Semen lactucae sativae 0.1-1, Lignum aquilariae resinatum 2-20, Fructus oryzae 1-5, Resina boswelliae carterii 0.1-1, Rhizoma atractylodis macrocephalae 0.1-1 and Semen cuscutae 0.1-1. The whole or the specific parts of the plants can be used to prepare the inventive pharmaceutical composition

preferred plants are Aquilariae lignum containing resin and Boswellia carterii containing resin. This pharmaceutical composition can be formulated into lozenge, tablet, film coated tablets, capsule, soft capsule, granule, powder, pill, solution, emulsion, injection solution, injection, ointment, cream, spray or inhalant.

Priority: WO2002CN00534 Applic. Date: 2002-08-02; CN20021019186 Applic. Date: 2002-05-14

Inventor: LIU SUYING [TW]; TSAL YIMING [TW]


Patent No.: US7459449B2  Issued: 02/Dec/2008

Title: Stable salts of olanzapine

Applicant/Assignee: SYNTHON IP INC

Application No.: 11/050852   Filing Date: 27/Jan/2005

Abstract:

Several salts of olanzapine, including olanzapine malonate, olanzapine glycolate, olanzapine maleate, and olanzapine benzoate, have been found to have favorable solid state characteristics.

Priority: US20040539120P Applic. Date: 2004-01-27; US20040569607P Applic. Date: 2004-05-11

Inventor: KELTJENS ROLF [NL]


Patent No.: US7465465B2  Issued: 16/Dec/2008

Title: Pharmaceutical formulation comprising lanthanum compounds

Applicant/Assignee: SHIRE BIOCHEM INC

Application No.: 10/926330   Filing Date: 26/Aug/2004

Abstract:

This invention relates to a chewable lanthanum formulation comprising a pharmaceutically effective amount of a lanthanum compound

and at least one chewable pharmaceutically acceptable excipient. This invention also relates to a pharmaceutical formulation in a tablet or in a powder comprising a pharmaceutically effective amount of a lanthanum compound produced by a process which comprises the steps of: a) powder blending the lanthanum compound and at least one pharmaceutically acceptable excipient in a mixer to form a mixture

or b) powder blending the lanthanum compound and excipients, compressing the resulting combination into a slug material or roller compacting the resulting combination into a strand material, and milling the prepared material into a free flowing mixture

and c) compressing the resulting mixture into a tablet or filing up the resulting mixture in a appropriate container.

Priority: US20030497560P Applic. Date: 2003-08-26; US20030517078P Applic. Date: 2003-11-05

Inventor: HASLAM ROBERT PAUL [GB]; TRESPIDI LAURA ANNA [IT]; FERDINANDO JOSEPHINE CHRISTINE [GB]

US Patents in Excipients, Delivery and Release of Pharmaceutical
Compositions and Actives Granted in 2008
US Patents Granted in 2009
US Patents Granted in 2007
...or use our Search Engine to
search for patent documents by
number.
Search for anything. Simply
type the words in the box..
LIST OF US PATENTS IN EXCIPIENTS, DELIVERY AND RELEASE OF PHARMACEUTICAL COMPOSITIONS GRANTED IN 2008
This list includes patents granted in the United States. The list was retrieved by searching the claims section of all patent applications. Salient search terms included pharmaceutical
formulations, excipients, strips, gums, cellulose, lozenge, tablets, capsules, suppositories; solid dosage, nasal inhalation; time, control or sustained drug release; polysaccharides,
polymeric excipients, hyaluronic acid, micro- and nano-spheres, carbomer, povidone, polyacrylates, polymerthacrylates; emulsions; enemas, vaginal, rectal, nasal, ocular or buccal
administration of medications and related subjects.
Clck to enlarge and view details